# US 11,028,393 B2 · siRNA compositions that specifically down regulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,028,393 B2
- Document ID: US11028393B2
- Status: Granted
- Kind: B2
- Application number: 16/735,034
- Filed: 2020-01-06
- Published: 2020-08-27
- Granted: 2021-06-08
- Earliest claimed: 2016-06-03
- Assignees: Purdue Research Foundation
- Applicants: Purdue Research Foundation
- Inventors: Wanqing Liu; Yoon Yeo
- Web page: https://patentgrep.com/patent/US11028393B2

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 47/554: {the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid}
- A61K 47/58: obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K 47/59: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 47/6933: {the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/351: Conjugate
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2320/34: Allele or polymorphism specific uses
- C12Y 301/01003: Triacylglycerol lipase (3.1.1.3)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

The invention provides siRNA compositions that specifically downregulates expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD).

## Claims

### Claim 1

A composition comprising a small interfering RNA (siRNA) molecule that specifically downregulates expression of a rs738409 C>G variant of a patatin-like phospholipase domain-containing (PNPLA3) gene, wherein the siRNA molecule comprises a nucleotide sequence of at least one of SEQ ID NOs 288-297.

### Claim 2 (depends on 1)

The composition according to claim 1, further comprising a nanoparticle to which the siRNA molecule is coupled.

### Claim 3 (depends on 2)

The composition according to claim 2, wherein the nanoparticle comprises low molecular weight polyethyleneimine (LPEI) and a lipid.

### Claim 4 (depends on 3)

The composition according to claim 3, wherein the lipid is a bile acid.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein the siRNA molecule does not downregulate expression of a wild-type isoform of the PNPLA3 gene.

### Claim 6 (depends on 1)

The composition according to claim 1, wherein the siRNA molecule comprises one or more non-naturally occurring nucleotides.

### Claim 7

A method for treating a subject with a chronic liver disease or alcoholic liver disease (ALD), the methods comprising administrating a therapeutically effective amount of a composition comprising a small interfering RNA (siRNA) molecule that specifically downregulates expression of a rs738409 C>G variant of a patatin-like phospholipase domain-containing (PNPLA3) gene, wherein the siRNA molecule comprises a nucleotide sequence of at least one of SEQ ID NOs 288-297.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the composition further comprises a nanoparticle to which the siRNA molecule is coupled.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the nanoparticle comprises low molecular weight polyethyleneimine (LPEI) and a lipid.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the lipid is a bile acid.

### Claim 11 (depends on 7)

The method according to claim 7, wherein the siRNA molecule comprises one or more non-naturally occurring nucleotides.
